Anixa Biosciences to Present Ovarian Cancer CAR-T Trial Findings at SGO Annual Meeting

Anixa Biosciences at the SGO Annual Meeting

Anixa Biosciences, Inc., a company specializing in cancer treatment and prevention, has announced that Dr. Robert Wenham, chair of the Gynecologic Oncology Department at Moffitt Cancer Center, will present the latest updates on its ovarian cancer CAR-T therapy. This presentation will take place during the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer scheduled from April 10 to April 13, 2026, in San Juan, Puerto Rico.

Overview of the Presentation

Dr. Wenham, as the principal investigator of Anixa’s ongoing clinical trial, will share insights regarding the Phase 1 trial of lira-cel, a CAR-T therapy that specifically targets the follicle-stimulating hormone receptor (FSHR). His talk, titled "Phase 1 clinical trial of autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer," will provide an overview of the trial design, objectives, and current progress.

The SGO Annual Meeting is recognized as a premier scientific conference for professionals dedicated to the treatment of gynecologic cancer. This event serves as a platform where experts share the latest advancements in research, exchange knowledge, and establish connections within the global oncology community.

About Lira-cel

Lira-cel, or liraltagene autoleucel, represents a groundbreaking approach in targeting ovarian cancer. This immunotherapy is engineered to recognize FSHR, which is predominantly found in ovarian cancer cells, minimizing impacts on healthy cells. The ongoing Phase 1 trial is designed for adult women who have recurrent ovarian cancer and have undergone at least two previous therapies. ClinicalTrials.gov Identifier for this trial is NCT05316129.

Anixa Biosciences: Company Profile

Anixa Biosciences is innovating within the biotechnology sector, primarily focusing on fighting cancer. The firm's flagship CAR-T therapy for ovarian cancer is being developed in collaboration with Moffitt Cancer Center, tapping into unique CAR-T technology that employs a chimeric endocrine receptor (CER-T) approach. This technology diverges from standard therapies as it leverages the natural ligand of the FSHR receptor instead of an antibody fragment, setting it apart from conventional CAR-Ts.

Moffitt Cancer Center is a global leader in advancing cancer immunotherapeutics, creating next-generation cell therapies, including CAR-T and tumor-infiltrating lymphocyte (TIL) therapies, that harness the body’s immune system against cancer.

In addition to its CAR-T initiatives, Anixa’s vaccine development endeavors include vaccines aimed at breast and ovarian cancers, crafted in partnership with the Cleveland Clinic. These vaccines target specific proteins linked to various cancers, marking a significant stride towards preventive cancer medicine.

Future Directions

Anixa's business model is built on collaborations with renowned research institutions at all stages of the therapeutic development pipeline. This strategic approach allows the company to perpetually explore and integrate emerging technologies conducive to cancer treatment innovation.

As the SGO Annual Meeting approaches, anticipation grows around Dr. Wenham's presentation and Anixa's commitment to advancing the field of gynecologic oncology. Industry professionals and stakeholders are eager to see how these clinical trials will pave the way for new treatment modalities that could potentially reshape the landscape of ovarian cancer care. For more updates, visit Anixa’s websites and follow their social media platforms for ongoing news and developments.

Conclusion

The unveiling of updates from Anixa Biosciences at the SGO provides a crucial glimpse into the future of ovarian cancer treatment. As research efforts continue to evolve, the hope remains that innovative solutions like lira-cel will significantly impact patient outcomes and contribute to the global fight against cancer.